Liu L, Simon B, Shi J, Mallhi AK, Eisen HJ. Impact of diabetes mellitus on risk of cardiovascular disease and all-cause mortality: evidence on health outcomes and antidiabetic treatment in United States adults. World J Diabetes. 2016;7:449–61.

Article  PubMed  PubMed Central  Google Scholar 

Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people. Lancet Diabetes Endocrinol. 2015;3(2):105–13.

Article  PubMed  PubMed Central  Google Scholar 

Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes [published correction appears in. Eur Heart J. 2023;44(48):5060.

Article  Google Scholar 

Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC State-of-the-Art Review [published correction appears in J Am Coll Cardiol. 2020 Sep 22;76(12):1505. 10.1016/j.jacc.2020.08.010]. J Am Coll Cardiol. 2020;75(4):422–34.

Article  CAS  PubMed  Google Scholar 

Basu D, Huggins L-A, Scerbo D, Obunike J, Mullick AE, et al. Mechanism of increased LDL (Low-Density lipoprotein) and decreased triglycerides with SGLT2 (Sodium-Glucose cotransporter 2) inhibition. Arterioscler Thromb Vasc Biol. 2018;38:2207–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bays HE, Sartipy P, Xu J, Sjostrom CD, Underberg JA. Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels. J Clin Lipido. 2017;11(2):450–8, e1.

Article  Google Scholar 

Bechmann LE, Emanuelsson F, Nordestgaard BG, Benn M. SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: Meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type. Atherosclerosis. 2024;394:117236.

Article  CAS  PubMed  Google Scholar 

Szekeres Z, Toth K, Szabados E. The Effects of SGLT2 Inhibitors on Lipid Metabolism. Metabolites. 2021;11(2):87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Osto E, Bonacina F, Pirillo A, Norata GD. Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: From clinical evidence to molecular mechanisms. Pharmacol Res. 2023;188:106667.

Article  CAS  PubMed  Google Scholar 

Wright EM. Glucose transport families SLC5 and SLC50. Mol Aspects Med. 2013;34(2–3):183–96.

Article  CAS  PubMed  Google Scholar 

Ferrannini E. Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab. 2017;26(1):27–38.

Article  CAS  PubMed  Google Scholar 

Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987;79:1510–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.

Article  CAS  PubMed  Google Scholar 

Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin cardiovascular assessment study). Circulation. 2018;137(4):323–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.

Article  CAS  PubMed  Google Scholar 

Patel SM, Kang YM, Im K, Neuen BL, Anker SD, Bhatt DL, Butler J, et al. Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis. Circulation. 2024;149(23):1789–801.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108–17. https://doi.org/10.1007/s00125-018-4670-7.

Article  CAS  PubMed  Google Scholar 

Sattar N, Fitchett D, Hantel S, Wanner C, Bluhmki E, Lachin JM, et al. SGLT2 inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia. 2016;59(7):1333–9.

Article  PubMed  PubMed Central  Google Scholar 

Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73(15):1931–44.

Article  CAS  PubMed  Google Scholar 

Su S, Ji X, Li T, Teng Y, Wang B, Han X, Zhao M. The changes of cardiac energy metabolism with sodium-glucose transporter 2 inhibitor therapy. Front Cardiovasc Med. 2023;10:1291450.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang K, Luo X, Liao B, Li G, Feng J. Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms. Cardiovasc Diabetol. 2023;22(1):86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stanigut AM, Pana C, Enciu M, Deacu M, Cimpineanu B, Tuta LA. Hypoxia-inducible factors and diabetic kidney disease-How deep can we go? Int J Mol Sci. 2022;23(18):10413.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sillars A, Sattar N. Management of lipid abnormalities in patients with diabetes. Curr Cardiol Rep. 2019;21(11):147 Published 2019 Nov 22.

Article  PubMed  PubMed Central  Google Scholar 

Hirano T. Pathophysiology of diabetic dyslipidemia. J Atheroscler Thromb. 2018;25(9):771–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bahiru E, Hsiao R, Phillipson D, Watson KE. Mechanisms and treatment of dyslipidemia in diabetes. Curr Cardiol Rep. 2021;23(4):26.

Article  PubMed  Google Scholar 

Lucero D, Zago V, López GI, et al. Does non-alcoholic fatty liver impair alterations of plasma lipoproteins and associated factors in metabolic syndrome? Clin Chim Acta. 2011;412(7–8):587–92.

Article  CAS  PubMed  Google Scholar 

Borén J, Taskinen MR, Packard CJ. Biosynthesis and metabolism of ApoB-containing lipoproteins. Annu Rev Nutr. 2024;44(1):179–204.

Article  PubMed  Google Scholar 

Borén J, Taskinen MR, Björnson E, Packard CJ. Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia. Nat Rev Cardiol. 2022;19(9):577–92.

Article  PubMed  Google Scholar 

Hayashi T, Fukui T, Nakanishi N, et al. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin [published correction appears in. Cardiovasc Diabetol. 2017;16(1):149.

Article  PubMed  PubMed Central  Google Scholar 

Lin XF, Cui XN, Yang J, et al. SGLT2 inhibitors ameliorate NAFLD in mice via downregulating PFKFB3, suppressing glycolysis and modulating macrophage polarization. Acta Pharmacol Sin. 2021;12:793586 Published online September 18, 2024.

Google Scholar 

Chehrehgosha H, Sohrabi MR, Ismail-Beigi F, et al. Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Diabetes Ther. 2021;12(3):843–61.